Integra Lifesciences Holdings (IART) Tops Q3 EPS by 9c; Adjusts FY12 EPS Outlook

Integra Lifesciences Holdings (NASDAQ: IART) reported Q3 EPS of $0.85, $0.09 better than the analyst estimate of $0.76. Revenue for the quarter came in at $210.1 million versus the consensus estimate of $211.51 million.

Integra Lifesciences Holdings sees FY2012 EPS of $3.04-3.09, versus the consensus of $3.04.

For earnings history and earnings-related data on Integra Lifesciences Holdings (IART) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
• Waste stocks ride AI and healthcare boom as CLH surges 27%